Disc Medicine Inc. has announced the commencement of an underwritten public offering totaling $220 million in shares of its common stock and pre-funded warrants. Of this amount, $200 million in shares will be offered by Disc Medicine, while $20 million will be offered by AI DMI LLC, a selling stockholder. Additionally, the selling stockholder plans to grant underwriters a 30-day option to purchase up to an additional $33 million in shares. Disc Medicine intends to use the net proceeds to support the potential commercialization of bitopertin for erythropoietic protoporphyria $(EPP)$ and X-linked protoporphyria $(XLP)$, fund ongoing research and clinical development, and for general corporate purposes. The company will not receive proceeds from shares sold by the selling stockholder. Jefferies, Leerink Partners, Morgan Stanley, and Cantor are acting as joint book-running managers for the proposed offering.